Printer Friendly

ADVANCED INTERVENTIONAL SYSTEMS RECEIVES MARKETING APPROVAL FOR SECOND GENERATION LASER

 IRVINE, Calif., Jan. 21 /PRNewswire/ -- Advanced Interventional Systems (NASDAQ: LAIS) today announced that the federal Food and Drug Administration has approved for commercial distribution its LAISer II excimer laser system for treating heart disease.
 According to LAIS Chairman and Chief Executive Officer Robert E. Wall the LAISer II unit received approval for indications identical to the DYMER(R) 200+ system, which received FDA approval for commercial marketing on Jan. 31, 1992.
 LAIS' excimer laser system is used to clear blocked coronary arteries in patients who cannot be favorably treated by balloon angioplasty alone.
 Wall said that the primary differences between the two laser units are in features such as size and user friendliness. "For example, the LAISer II unit weighs approximately 50 percent less than our first model, the DYMER 200+. But although we have dramatically reduced the size of the LAISer II unit, we have preserved the same superior laser beam profile, the 200 nanosecond pulse width, and the high energy level that are integral parts of the DYMER 200+ unit. However, because the LAISer II unit is a smaller and lighter laser source, it increases user convenience and allows for quicker clinical response.
 "In addition, when designing the LAISer II unit we added features such as an instant on' and permanent optical alignment of the laser beam which will decrease the time required for preparing the system for use in the hospital cath labs," he said.
 Having received FDA approval to commercially market the unit, the company will move forward with its plan to increase production levels. The LAISer II units are expected to be available for shipment to hospitals by the end of this year. In the meantime, LAIS will continue to sell its DYMER 200+ system and provide customers the opportunity to trade-up to the LAISer II unit when it becomes available. "Because of the quality of its design and manufacturing, we believe the DYMER 200+ system remains a premier excimer laser system that continues to serve well the clinical need of our customers," Wall said.
 Advanced Interventional Systems pioneered the procedure for treating heart disease with an excimer laser system and is the first and, to date, the only company to receive approval from the FDA to market a laser system for clearing blocked arteries in the heart. The company is committed to ongoing technological advances that further expand the clinical utility of excimer laser angioplasty. LAIS was founded in 1986 and completed its initial public offering in November 1991.
 -0- 1/21/93
 /CONTACT: Connie McCluskey, director-corporate communications of Advanced Interventional Systems, 714-586-1342 or 714-581-8510, ext. 234/
 (LAIS)


CO: Advanced Interventional Systems ST: California IN: MTC SU:

LS-KJ -- LA005 -- 7244 01/21/93 09:00 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 21, 1993
Words:452
Previous Article:BERGEN BRUNSWIG CORP. CALLS FOR REDEMPTION OF ALL OF ITS LIQUID YIELD OPTION(TM) NOTES DUE 2004
Next Article:FAIRSTAR CRUISES ANNOUNCES ITS UNIQUE DISCOVER AUSTRALIA CRUISE
Topics:


Related Articles
ADVANCED INTERVENTIONAL SYSTEMS RECEIVES FDA PRE-MARKET APPROVAL
ADVANCED INTERVENTIONAL SYSTEMS REPORTS FISCAL 1991 RESULTS; FINANCIAL PERFORMANCE CONSISTENT WITH RECENT ANALYST PROJECTIONS
ADVANCED INTERVENTIONAL SYSTEMS SIGNS LETTER OF INTENT TO ACQUIRE SUPPLIER OF FIBER OPTICS
LAIS ANNOUNCES PLANS TO REPURCHASE STOCK
ADVANCED INTERVENTIONAL SYSTEMS COMPLETES ACQUISITION OF POLYMICRO TECHNOLOGIES INC.
ADVANCED INTERVENTIONAL SYSTEMS ANNOUNCES SECOND QUARTER RESULTS
ADVANCED INTERVENTIONAL SYSTEMS ANNOUNCES VICE PRESIDENT OF SALES
ADVANCED INTERVENTIONAL SYSTEMS ANNOUNCES TERMINATION OF MERGER AGREEMENT AND RESTRUCTURING
ROBERT E. WALL RETIRES AS CHAIRMAN & CHIEF EXECUTIVE OFFICER OF ADVANCED INTERVENTIONAL SYSTEMS INC.
Spectranetics Receives Approval to Market its Largest Laser Coronary Angioplasty Catheter for Use in Europe.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters